Aescap, alongside other existing backers and new strategic investors Debiopharm Group and Johnson & Johnson, has particpated in a €30m series B funding round for Biocartis SA.
Austria-based electrical engineering company had filed for insolvency in April 2020
VC house expects to hold a €35-45m first close by the end of July and a final close in around one year
LPs in Exponent III include Aberdeen Standard Investments, Central Pension Fund and CNP Assurances
Company has generated €12m in revenues and has a 25% EBITDA margin